title: Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
abstract: Forty-four isolates belonging to human pathogenic species of Lichtheimia were tested against nine antifungal agents by using the EUCAST methodology. No remarkable differences were found between the clinical species, although L. ramosa showed slightly higher MICs for all drugs. Amphotericin B was the most active drug. Among azole drugs, posaconazole had the best activity in vitro and voriconazole was inactive. Echinocandins showed activity for some isolates, suggesting a potential role in combination therapy.
authors.affiliation: Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Alastruey-Izquierdo
authors.forename: Isabel
authors.initials: I
authors.lastname: Cuesta
authors.forename: Grit
authors.initials: G
authors.lastname: Walther
authors.forename: Manuel
authors.initials: M
authors.lastname: Cuenca-Estrella
authors.forename: Juan Luis
authors.initials: JL
authors.lastname: Rodriguez-Tudela
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009090:Mucorales / Q000187:drug effects*; D011743:Pyrimidines / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; C101425:posaconazole; D000666:Amphotericin B; D065819:Voriconazole